Clinical Insights into the COMMANDS Trial
The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
EP: 1.Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment
Now Viewing
EP: 2.Clinical Insights into the COMMANDS Trial
EP: 3.Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?
EP: 4.MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS
EP: 5.Recent Updates for Second-Line Treatment Options in Lower-Risk MDS
EP: 6.Clinical Implications of Recent Data on New Agents in Lower-Risk MDS
EP: 7.Real-World Data for Luspatercept in Lower-Risk MDS
EP: 8.Treatment Strategies and Sequencing in MDS
EP: 9.Unmet Needs and Future of Lower-Risk MDS
Related Videos
Related Content
